Stay updated with breaking news from Breakthrough Device. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Datar Cancer Genetics Inc announced today that the US Food and Drug Administration (FDA) has granted 'Breakthrough Device Designation' for its...
The liquid biopsy has been developed by Datar Cancer Genetics to help diagnose brain tumors where a conventional biopsy is not possible. A prospective, blinded study by a research team
Synchron, the endovascular brain-computer interface company, announced today an oversubscribed $75 million Series C financing round.
Australian Tom Oxley’s Synchron has become the centre of attention for three of the world’s richest people.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!